TrialCancer immunology, immunotherapy : CII2011

Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used.

W Joost Lesterhuis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.